Maria Fardis, Ph.D., President and CEO
San Carlos, CA
(NASDAQ: IOVA)
Iovance Biotherapeutics is working to treat cancer by developing immuno-oncology Tumor Infiltrating Lymphocytes (TIL) therapies that harness a patient’s own immune system. Iovance is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized TIL for the treatment of solid tumors. The company’s TIL technology is designed to address the various obstacles that reduce the natural anti-tumor immune response in the body. The company is conducting four Phase II clinical trials to assess the efficacy and safety of TILs for treatment of patients with metastatic melanoma, squamous cell carcinoma of the head and heck, metastatic non-small cell lung cancer (NSCLC), and cervical cancer. The company is also studying TIL therapy in ovarian cancer and sarcomas. The company aims to change the cancer treatment paradigm by developing and optimizing TIL therapy to help support the patient’s own immune system in fighting various cancers.
www.iovance.com